CANDEL THERAPEUTICS CADL 深 沪
等待开盘 10-21 09:30:00 美东时间
5.54
+0.210
+3.94%
华盛通- 最 高5.643
- 今 开5.38
- 成交量 65.70万股
- 最 低 5.36
- 昨 收 5.33
- 总市值 3.04亿
- 52周最高 14.60
- 市盈率 静 --
- 换手率 1.20%
- 52周最低 3.785
- 委 比 77.30%
- 总股本 5489.51万
- 历史最高 14.78
- 量 比 0.60
- 振 幅 5.31%
- 历史最低 0.66
- 每 手 1
- 风险率 3.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
Candel Therapeutics appoints Bali Pulendran, Ph.D., a leading expert in systems immunology, to its Research Advisory Board. His加入 will support the advancement of Candel's viral immunotherapy candidates, CAN-2409 and CAN-3110, targeting solid tumors and recurrent high-grade glioma, respectively. With a proven track record in human immunology, Pulendran's expertise will enhance the development of innovative therapies to combat cancer across multipl...
10-16 12:05
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Strata Skin Sciences (NASDAQ:SSKN) shares increased by 44.9% to $2.23 ...
10-15 01:06
Candel Therapeutics Secures $130M Loan Facility To Fund Phase 3 Trial And Advance Cancer Pipeline
$50 million drawn down at closing, with access to up to an additional $80 millionStrengthens Company's financial position; enables initiation of phase 3 clinical trial of CAN-2409 in non-small cell lung cancer
10-14 20:14
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
Candel Therapeutics announced a $130 million term loan facility with Trinity Capital to strengthen its financial position and support the phase 3 clinical trial of CAN-2409 in non-small cell lung cancer (NSCLC). The first tranche of $50 million has been drawn, with up to $80 million additional available. Proceeds will also prepare for a potential commercial launch in early localized prostate cancer. Candel highlights disciplined capital allocatio...
10-14 12:10
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
Candel Therapeutics announced encouraging interim data from its ongoing phase 1b clinical trial of CAN-3110 for recurrent glioblastoma, with updated survival data showing a median overall survival of 11.8 and 12.0 months for arms A and B, respectively. CAN-3110, a viral immunotherapy, was shown to dynamically remodel the tumor microenvironment, with biopsy analyses revealing immune activation and tumor cell replacement by immune cells. A complete...
10-14 12:05
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
Candel Therapeutics will present data from its enLIGHTEN™ Discovery Platform and CAN-2409 program in NSCLC at the SITC Annual Meeting. Dr. Paul Peter Tak will discuss positive phase 3 results for CAN-2409 in prostate cancer. Researchers will present on the multimodal immunotherapy approach and immune responses in NSCLC, highlighting improved survival in ICI-refractory patients. CAN-2409 has received multiple FDA designations, including Regenerati...
10-03 13:05
美股大行评级 | 潜在涨幅207.38%！GoldMining获HC Wainwright升目标价至3.75美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持GoldMining"买入"评级，目标价从3.25美元升至3.75美元；摩根士丹利：维持Crinetics Pharmaceuticals"超配"评级，目标价从65美元升至77美元
09-30 14:16
Candel Therapeutics Announces CAN-2409 Significantly Improves Disease-Free Survival In Prostate Cancer, Showing Benefit Across Radiation Modalities In Phase 3 Trial
CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to placebo in patients treated with either conventional or moderate hypofractionated radiotherapy with curative intent, independent of the specific modality of radiation therapy usedNEEDHAM, Mass., Sept.
09-29 20:20
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
Candel Therapeutics will present CAN-2409 Phase 3 trial data for intermediate-to-high-risk localized prostate cancer at ASTRO 2025. The oral presentation, featuring Glen Gejerman, MD, MBA, highlights CAN-2409's combination with external beam radiation. The abstract was selected for ASTRO’s Science Highlights. CAN-2409 has received multiple FDA designations, including Fast Track and Orphan Drug, and demonstrated positive results in phase 2a trials...
09-17 12:05
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Pelthos Therapeutics (AMEX:PTHS) stock increased by 25.9% to $28.27 du...
09-04 01:06
